GSK discontinues Beano claim
This article was originally published in The Tan Sheet
Executive SummaryGlaxoSmithKline Consumer Healthcare disagrees with the Electronic Retailing Self-Regulation Program's determination that the firm failed to support an exclusivity claim for its Beano supplement, but will qualify the claim in future ads, the firm says. The Council of Better Business Bureaus arm's inquiry was conducted after an anonymous competitor complained about a statement on Beano's Web site. The claim, "The only product available that can help prevent gas," was discontinued during the review, but GSK reserved the right to use the statement in future advertising. It defended its position with literature and noted Beano's biggest competitors, including Gas-X, relieve rather than prevent gas. However, ERSP determined the evidence was insufficient in showing that competing products were "ineffective in preventing gas" and that the statement was therefore inaccurate...
You may also be interested in...
Submission surge in late 2019 means a spike in late summer 2020 user fee goals, including 16 novel agents in August alone.
Keeping Track: Approvals For Tazverik And Tepezza, Priority Reviews For Belantamab Mafodotin And Lynparza
The latest drug development news and highlights from our US FDA Performance Tracker.
Accelerated approval in epithelial sarcoma may de-risk the firm’s goals for approval of Tazverik in follicular lymphoma and other larger indications.